These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 21703882)
1. Cerebral signal intensity abnormalities on T2-weighted MR images in HIV patients with highly active antiretroviral therapy: relationship with clinical parameters and interval changes. Hanning U; Husstedt IW; Niederstadt TU; Evers S; Heindel W; Kloska SP Acad Radiol; 2011 Sep; 18(9):1144-50. PubMed ID: 21703882 [TBL] [Abstract][Full Text] [Related]
2. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study. Liu ZY; Guo FP; Han Y; Qiu ZF; Zuo LY; Li YL; Li TS Chin Med J (Engl); 2009 Oct; 122(20):2497-502. PubMed ID: 20079166 [TBL] [Abstract][Full Text] [Related]
3. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy. Gandhi T; Wei W; Amin K; Kazanjian P Clin Infect Dis; 2006 Mar; 42(6):878-84. PubMed ID: 16477568 [TBL] [Abstract][Full Text] [Related]
4. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Moore RD; Keruly JC Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456 [TBL] [Abstract][Full Text] [Related]
5. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217 [TBL] [Abstract][Full Text] [Related]
6. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544 [TBL] [Abstract][Full Text] [Related]
7. Persistent brain abnormalities in antiretroviral-naive HIV patients 3 months after HAART. Chang L; Ernst T; Witt MD; Ames N; Walot I; Jovicich J; DeSilva M; Trivedi N; Speck O; Miller EN Antivir Ther; 2003 Feb; 8(1):17-26. PubMed ID: 12713060 [TBL] [Abstract][Full Text] [Related]
8. Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3. Toulson AR; Harrigan R; Heath K; Yip B; Brumme ZL; Harris M; Hogg RS; Montaner JS J Infect Dis; 2005 Nov; 192(10):1787-93. PubMed ID: 16235178 [TBL] [Abstract][Full Text] [Related]
9. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings. Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384 [TBL] [Abstract][Full Text] [Related]
10. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study. McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741 [TBL] [Abstract][Full Text] [Related]
11. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)]. Panel de expertos de Gesida y Plan Nacional sobre el Sida Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124 [TBL] [Abstract][Full Text] [Related]
12. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up. Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A; Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566 [TBL] [Abstract][Full Text] [Related]
13. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)]. Panel de expertos de GESIDA y Plan Nacional sobre el Sida Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714 [TBL] [Abstract][Full Text] [Related]
14. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Fagard C; Oxenius A; Günthard H; Garcia F; Le Braz M; Mestre G; Battegay M; Furrer H; Vernazza P; Bernasconi E; Telenti A; Weber R; Leduc D; Yerly S; Price D; Dawson SJ; Klimkait T; Perneger TV; McLean A; Clotet B; Gatell JM; Perrin L; Plana M; Phillips R; Hirschel B; Arch Intern Med; 2003 May; 163(10):1220-6. PubMed ID: 12767960 [TBL] [Abstract][Full Text] [Related]
15. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ; Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251 [TBL] [Abstract][Full Text] [Related]